Improved Treatment of Pancreatic Cancer by IL-12 and B7.1 Costimulation: Antitumor Efficacy and Immunoregulation in a Nonimmunogenic Tumor Model

This publication has 36 references indexed in Scilit:

• Improved safety through tamoxifen-regulated induction of cytotoxic genes delivered by Ad vectors for cancer gene therapy
  Gene Therapy, 2000
• Adenoviral Gene Transfer of Interleukin 12 into Tumors Synergizes with Adoptive T Cell Therapy Both at the Induction and Effector Level
  Human Gene Therapy, 2000
• Autologous lymphocyte responses to adenovirus-B7-1-transduced human cancer cells
  Cancer Gene Therapy, 1999
• Interleukin-12 requires initial CD80-mediated T-cell activation to support immune responses toward human breast and ovarian carcinoma
  Cancer Gene Therapy, 1999
• Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte–macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunity
  Gene Therapy, 1998
• Lack of correlation between rejection of tumor cells co‐expressing interleukin‐2 and B7.1 and vaccine efficiency
  European Journal of Immunology, 1997
• Triggering of Natural Killer Cells by the Costimulatory Molecule CD80 (B7-1)
  Immunity, 1996
• Murine Models of Cancer Cytokine Gene Therapy Using Interleukin‐12a
  Annals of the New York Academy of Sciences, 1996
• Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines
  Surgery, 1996
• Tumor-rejection antigens recognized by T lymphocytes
  Current Opinion in Immunology, 1993